Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Shares Purchased by Rhumbline Advisers

Rhumbline Advisers raised its stake in shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) by 20.1% during the second quarter, Holdings Channel.com reports. The institutional investor owned 76,981 shares of the biotechnology company’s stock after buying an additional 12,907 shares during the period. Rhumbline Advisers’ holdings in Aldeyra Therapeutics were worth $255,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of the stock. Panagora Asset Management Inc. acquired a new stake in shares of Aldeyra Therapeutics during the second quarter valued at $200,000. Bank of New York Mellon Corp lifted its holdings in Aldeyra Therapeutics by 21.7% in the 2nd quarter. Bank of New York Mellon Corp now owns 195,722 shares of the biotechnology company’s stock valued at $648,000 after purchasing an additional 34,885 shares in the last quarter. Hennion & Walsh Asset Management Inc. boosted its stake in shares of Aldeyra Therapeutics by 8.6% during the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 88,122 shares of the biotechnology company’s stock worth $292,000 after purchasing an additional 6,944 shares during the last quarter. Diversified Trust Co purchased a new stake in shares of Aldeyra Therapeutics during the second quarter worth about $41,000. Finally, SG Americas Securities LLC acquired a new position in shares of Aldeyra Therapeutics in the second quarter valued at approximately $38,000. Hedge funds and other institutional investors own 59.71% of the company’s stock.

Aldeyra Therapeutics Stock Performance

Aldeyra Therapeutics stock opened at $5.50 on Friday. Aldeyra Therapeutics, Inc has a 1 year low of $1.42 and a 1 year high of $6.74. The firm’s 50-day moving average is $5.09 and its 200-day moving average is $4.19. The company has a market cap of $326.78 million, a P/E ratio of -10.78 and a beta of 1.45.

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $10.00 target price on shares of Aldeyra Therapeutics in a research note on Friday, August 9th.

Aldeyra Therapeutics Company Profile

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-?B, inflammasomes, and Scavenger Receptor A.